This is a method for measuring tripeptide aminopeptidase (EC 3.4.11.4) activity in serum. L-Leucylglycylglycine is used as substrate, and the reaction is followed by monitoring the absorbance increase at 340 nm when NAD is reduced to NADH in the presence of an excess of leucine dehydrogenase. This principle allows kinetic determination of the enzyme without interference by carboxypeptidases. Amastatin is added to the reaction mixture to prevent nonspecific hydrolysis of the substrate catalyzed by other aminopeptidases. As final reaction concentrations we recommend (per liter): 100 mmol of Tris buffer (pH 8.2), 4.0 mmol of L-leucylglycylglycine, 10 kU of leucine dehydrogenase, 3.8 mmol of NAD, and 85 mol of amastatin. The assay is suited to modern enzyme analyzers and has high precision.
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Tripeptide aininopeptidase (EC 3.4.11.4, a-aminoacyl-dipeptide hydrolase; TAP) catalyzes the hydrolysis of tripeptides at their N-terminal peptide bond to form a free amino acid and a dipeptide. The usual substrate for the activity measurement of TAP is triglycine or i-leucylglycylglycine (Leu-Gly-Gly), but leucine aminopeptidase (EC 3.4.11.1), arylaniidase (EC 3.4.11.2), and cystyl-aminopeptidase (EC 3.4.11.3) also catalyze the hydrolysis of these tripeptides just as TAP does. No specific assay method for TAP activity has been established, although the clinical significance of serum TAP has been discussed by many investigators
(1-4).
Here we describe a specific kinetic assay for TAP activity in serum, with Leu-Gly-Gly as substrate, leucine dehydrogenase as indicator enzyme, and amastatin as inhibitor of other aminopeptidases. To ensure optimal conditions, we tested various concentrations of the above-mentioned solutions, except for the 4.26 mmol/L NAD [10-fold the Km value of leucine dehydrogenase (5) as a final concentration].
Materials and Methods

Apparatus
We adjusted the pH of the solutions at 37 #{176}C, using calibration buffers (Kanto Chemical Co. Inc., Tokyo, Japan).
Samples
Leucine aminopeptidase and arylamidase were partly purified from liver by the method of Niinobe and Fujii (6), cystyl-aminopeptidase from placenta by the same method, and TAP from plasma by the method previously described (7) . Serum samples were from the Clinical Laboratory of Hamamatsu University Hospital; they were stored at 4#{176}C until assay.
Results
pH. We measured TAP activity in 100 mmolfL Ths HC1 buffer in the pH interval 7.2 to 9.2. Activity was greatest between pH 8.0 and 8.4 ( Figure 1 ); pH 8.2 is the optimal value.
Substrate
concentration.
The effect of Leu-Gly-Gly concentration on TAP activity was examined and the Michaelis constant (Jm) was determined by use of Lineweaver-Burk plots ( Figure 2 ). TAP activity increased with increasing substrate concentration up to 10 mmol/L Leu-Gly-Gly, and we calculated the apparent Km value to be 0.41 mmol/L. We used a final substrate concentration of 4.0 mmol/L, approximately 10-fold the Km value, which gave a zero-order rate reaction.
Leucine dehydrogenase concentration.
The relationship between apparent TAP activity and concentration of leucine dehydrogenase was investigated by the use of sera with low and high TAP activities. Apparent TAP activity reached a To prevent nonspecific hydrolysis of the substrate catalyzed by leucine aminopeptidase, arylamidase, and cystylaminopeptidase, we added amastatin to the reaction mixture. This inhibitor does not affect TAP, but it strongly inhibits other aminopeptidases; their residual activities at the 85 mol/L concentration of amastatin were <2% of those without the inhibitor (Figure 4) . Table 1 shows the inhibitory effect of 85 imol of amastatin per liter on aminopeptidases added to pooled serum. Essentially the same result was obtained for individual serum samples. Table 2 shows the result of an analytical-recovery study. Recoveries of TAP added to pooled serum at 66-199 U/L were essentially quantitative.
Linearity.
Hydrolysis
Precision. Table 3 shows our precision data. Sera with low and high activities were assayed to estimate the within-run variation. To estimate the between-day variation, we divided a pooled serum into seven portions and stored them at -70 #{176}C, then assayed on seven different days.
Stability of TAP.
A pooled serum with an activity of 118 U/L was divided into four lots, which we stored at 37,4, -15, and -70 #{176}C. By 10 days the activity had decreased by only 4% at -70 #{176}C and 6% at 4#{176}C. In contrast, the decrease alter only two days was 15% at -15 #{176}C and 80% at 37 #{176}C ( Figure  7 ). Thus we recommend storing samples at 4#{176}C and assaying their activities within a week.
Reference interval. TAP activity was determined in the sera of 46 ostensibly healthy laboratory workers (24 men, 22 women, ages 22-47 years). The normal reference interval (mean ± 2 SD) was 44-104 UIL. 
Discussion
Triglycine or Leu-Gly-Gly are used as substrate for the routine assay of serum TAP, and the reaction is usually (c) With Leu-Gly-Gly as substrate and leucine dehydrogenase as indicator enzyme, this method obviates interference by carboxypeptidases. We determined leucine dehydrogenase activity in the reaction mixture to be 1.6 kU/L. Theoretical studies on coupled enzyme assay were reported by McClure (10) and Takagahara et al. (11) . If the Km value of leucine dehydrogenase with L-leucine is 1 mmol/L (5), the proposed method can follow 96% of the true reaction rate up to 500 U of TAP activity per liter according to Takagahara's theory.
The clinical significance of TAP in serum remains obscure, although we recently reported the diagnostic usefulness of its assay in lymphoproliferative diseases (1) . This method will be a powerful tool in further investigation of this.
